Molybdenum disulfide (MoS 2 )-based drug delivery systems have shown considerable potential in cancer nanomedicines. In this work, a multifunctional nanoplatform comprising MoS 2 nanosheets decorated with copper sulfide (CuS) and further functionalized with polyethylene glycol (PEG) is reported. The resultant material has a particle size of approximately 115 nm, and can be loaded with doxorubicin (DOX) to a loading capacity of 162.3 mg DOX per g of carrier. Drug release is triggered by two stimuli (near infrared (NIR) irradiation and pH), and the carrier is shown to have excellent colloidal stability. The presence of both MoS 2 and CuS leads to very high photothermal conversion efficiency (higher than with MoS 2 alone). In vitro experiments revealed that the blank CuS-MoS 2 -SH-PEG carrier is biocompatible, but that the synergistic application of chemo-photothermal therapy (in the form of CuS-MoS 2 -SH-PEG loaded with DOX and NIR irradiation) led to greater cell death than either chemotherapy (CuS-MoS 2 -SH-PEG(DOX) but no NIR) or photothermal therapy (CuS-MoS 2 -SH-PEG with NIR). A cellular uptake study demonstrated that the nanoplatform can efficiently enter tumor cells, and that uptake is enhanced when NIR is applied. Overall, the functionalized MoS 2 material developed in this work exhibits great potential as an efficient system for dual responsive drug delivery and synergistic chemo-photothermal therapy. The route employed in our work thus provides a strategy to enhance photothermal efficacy for transition metal dichalcogenide drug delivery systems.
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Introduction
Chemotherapy is one of the most commonly used approaches in clinical cancer therapy. It is able to kill metastatic cancer cells efficiently, as well as preventing cell proliferation, but despite this the incidence rate of cancer continues to increase [1] . Furthermore, chemotherapy is not specific to cancer cells, but rather affects all cells simultaneously: this leads to systemic toxicity and damage to healthy tissues. The design of drug delivery systems able to give controlled and targeted release of a chemotherapeutic payload is thus much explored, because they can greatly reduce the side effects of chemotherapy [2] .
An alternative to chemotherapy is photothermal therapy (PTT), which is based on the conversion of near infra-red (NIR) light into heat. Absorption of NIR by a photothermal platform located in a tumor can cause thermal ablation, and thus a tumor can be destroyed without recourse to chemical therapies [3] [4] [5] [6] . PTT has advantages over chemotherapy in that it provides greater local treatment efficacy, and only minimal systemic side effects. However, there are also disadvantages in terms of the inability of NIR irradiation to penetrate deep into tissues, the risk of inhomogeneous heat distribution, and the possibility that tumor cells will become heat resistant [7] [8] [9] .
A significant number of nanoscale platforms have been investigated to ameliorate these problems. For instance, much attention has been paid to efficient NIR light absorbing materials such as gold nanostructures, copper chalcogenides, graphene, MoS 2 and carbon nanotubes, among others [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Researchers have also increasingly begun to recognize the synergistic potential of combining PTT and 5 / 31 chemotherapy in so-called chemo-photothermal therapy. Materials can be designed that both have PTT properties, leading to elevated local temperatures and direct ablation of tumor cells, and where the raised temperature also facilitates drug release from the carrier and enhances uptake by increasing cellular membrane permeability [20, 25] . This offers the possibility of locally delivering a chemotherapeutic to a tumor, massively reducing the systemic side effects. A number of studies have demonstrated that chemo-photothermal therapy has enhanced therapeutic efficiency over either photothermal or chemotherapy alone [26] [27] [28] [29] [30] [31] [32] .
Stimuli-responsive carriers have the ability to control drug release in response to triggers such as light, magnetic fields, temperature, ultrasound, and pH [33] [34] [35] . The blood and tissue of the human body have a roughly neutral pH, while tumors are weakly acidic, and the endosomes in which most materials enter cells have a pH of about 5.0 [36] . These differences can be exploited in pH-targeted drug delivery: for instance, the anti-cancer drug doxorubicin (DOX) is basic, and thus will dissolve more freely at acidic pHs than at neutral pH. A potential carrier for DOX is MoS 2 , a layered inorganic solid which responds to NIR irradiation. MoS 2 has been shown to be less toxic than graphene [37] , and has been explored as a stimulus-responsive drug carrier in a number of studies [19, [38] [39] [40] . There remains room for improvement in its PTT efficacy, however.
To achieve this improvement, the formation of a composite with an additional functional component can be a powerful approach. For MoS 2 , copper sulfide (CuS) nanoparticles are suitable in this regard. CuS is low cost and easily synthesized, and 6 / 31 has low cytotoxicity, high stability, and strong NIR absorption [41] . It has been reported that when CuS nanoparticles are grafted on the surface of two-dimensional materials the photothermal conversion efficiency of the nanocomposites improves [42, 43] .
In this work, CuS modified MoS 2 -nanosheets were prepared, with the aim of developing a dual responsive delivery system for chemo-photothermal therapy (Scheme 1). Further, polyethylene glycol thiol (PEG-SH) was incorporated into the nanocomposites to improve biocompatibility and colloidal stability, and the materials loaded with a doxorubicin (DOX) payload. The materials were fully characterized, and their drug release profiles, in vitro cytotoxicity and cellular uptake were explored.
The novel drug delivery system produced appears to be a promising therapeutic agent for biomedical applications. 
Preparation of MoS 2 nanosheets
2 g of MoS 2 was stirred with a solution of n-butyl lithium in hexane (2 mL, 1.6 M) for 48 h under an N 2 atmosphere. After intercalation of lithium was complete, the mixture was washed with hexane to remove residual n-butyl lithium, and the solid product recovered. 30 mL water was added to this product, and the suspension ultrasonicated for 90 min to achieve effective exfoliation. Subsequently, the suspension was centrifuged at 3000 rpm three times to separate the multilayered MoS 2 8 / 31
nanosheets and excess LiOH. The exfoliated MoS 2 was dialyzed against water for 5 days using a cellulose membrane (molecular weight cut-off (MWCO): 10 kDa) to obtain a pure product.
Preparation of CuS-MoS 2 nanosheets
3 mL of CuCl 2 solution (1.60 mg CuCl 2 , in water) was added to 2 mL of an aqueous suspension containing varied amounts of exfoliated MoS 2 (0.40, 0.80, 1.60, 3.20 or 6.40 mg, in water) and stirred for 2 h. Subsequently, 240 μL of Na 2 S solution (50 ×10 −3 M, in water) was added to the reaction mixture, with stirring for 5 min. This mixture was transferred to a water bath at 90 °C and stirred for 10 min. The resultant precipitate was dialyzed against water for 3 days using a cellulose membrane (MWCO: 10 kDa) to obtain CuS-MoS 2 nanosheets.
Functionalization of CuS-MoS 2 nanosheets
SH-PEG (1 mg/mL in water, 5 mL) was added to 2 mL of an aqueous CuS-MoS 2 nanosheet suspension (0.5 mg/mL). After ultrasonication for 30 min, reaction was allowed to proceed for 12 h at room temperature overnight to obtain CuS-MoS 2 -SH-PEG. The final product was suspended in water (15 mL) and centrifuged at 8,000 rpm three times to obtain pure CuS-MoS 2 -SH-PEG.
Drug loading
DOX was mixed with CuS-MoS 2 -SH-PEG in water and stirred at room temperature overnight. The supernatant was collected by centrifugation and the unloaded DOX concentration determined by UV-vis spectroscopy (UV3600 instrument, Shimadzu Corporation). Experiments were performed with a range of DOX:
CuS-MoS 2 -SH-PEG ratios in order to identify the optimum reaction conditions.
Materials characterization
The 
In vitro drug release
To investigate the NIR and pH responsive release behavior of the formulations, the Additional experiments were performed where the formulation was additionally exposed to 808 nm laser irradiation (1 W/cm 2 ) for 5 min periodically during the study.
The temperature was maintained at 37 °C for all experiments. The concentration of DOX in the release medium was quantified with UV-vis spectroscopy at 480 nm. The where h is the heat transfer coefficient, S the surface area, T max the equilibrium temperature, T am the ambient temperature, Q 0 the heat absorption of the quartz cell, I the laser power, and A the absorbance of CuS-MoS 2 -SH-PEG at 808 nm.
Cytotoxicity assays
The The MTT reagent (10 μL, 5 mg/mL) was added after 24 hours of culture (5% CO 2 , 37 ºC). This was followed by incubation at 37 °C in a 5% CO 2 atmosphere for 4 h.
The supernatant was carefully removed, and the MTT-formazan produced by living cells solubilized in 150 µL of DMSO for 20 min. Finally, the absorbance at 490 nm was measured using a microplate reader (MULTSIKAN MK3, ThermoFisher). Cell viability (%) was determined from the absorbance at 450 nm and normalized to negative control wells containing untreated cells.
In vitro cellular uptake
Cell targeting efficiency was investigated with confocal laser scanning microscopy (CLSM). MCF-7 cells were seeded in a 24-well plate (1×10 5 cells per well, 1 mL) and grown for 24 h. The media was aspirated and 2 mL of fresh DMEM containing free DOX or CuS-MoS 2 -SH-PEG(DOX) was added (at a DOX concentration of 3 μg/mL).
3 h later, the cells were rinsed three times with 1 mL of PBS (pH 7.4, 15 min per rinse). Subsequently, the nuclei were stained with DAPI solution and the cells imaged using a Nikon Eclipse Ti-S microscope.
Statistical analysis
All experiments were repeated three times. The data are displayed as mean ± standard deviation (S.D.). One-way analysis of variance (ANOVA) followed by a post hoc ukey's test was used for comparison between different groups. Statistical significance was considered at P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***).
Results and discussion

Synthesis and characterization of nanocomposites
The strategy underlying the construction of the CuS-MoS 2 -SH-PEG nanocomposites is illustrated in Scheme S1 (Supplementary Information). MoS 2 nanosheets were prepared through a chemical exfoliation protocol, following a previously reported method [26] . Subsequently, CuS nanoparticles were deposited on the surface, giving
CuS-MoS 2 [43] . SH-PEG was finally grafted onto the surface of CuS-MoS 2 via a thiol reaction. IR spectra (Fig. 1 where stated otherwise. of the MoS 2 can be seen to be decorated with numerous CuS NPs. XPS data for MoS 2 (Fig. 3a) 114.5 nm, which is appropriate for use as a cell-targeted drug delivery system [46] .
In vitro drug release
The DOX loading on the nanoparticles was explored as a function of the mass ratio of CuS-MoS 2 -SH-PEG to DOX. When the mass ratio was 2:1, 162.3 ± 9.1 mg DOX could be loaded per g of carrier (Table S1) [47] . The release of DOX was faster with laser irradiation than without, which allows release to be triggered by exposure to NIR. Compared to a previous study exploring functionalized MoS 2 delivery systems for DOX, the effect of NIR on DOX release is more apparent here [48] . This can be attributed to the enhanced photothermal efficacy of the CuS modified MoS 2 -nanosheets. 
Photothermal activity
The use of different mass ratios of CuCl 2 to MoS 2 in the preparation of CuS-MoS 2 led to the nanocomposites having varying photothermal conversion efficiency (Fig. 5a ).
The CuS-MoS 2 -SH-PEG system generated with a 1:1 mass ratio of CuCl 2 to MoS 2 was used as a baseline, and temperature increases with other mass ratios expressed as a percentage increase on this. At the same laser power and concentration, a CuCl 2 :
MoS 2 ratio of 2:1 leads to the greatest increases in temperature. The photothermal effect of the 2:1 system is found to be concentration-dependent under a fixed irradiation intensity of 0.5 W/cm 2 (Fig. 5b) . It also increases with power intensity for a fixed concentration suspension at 0.5mg/mL (Fig. 5c ).
The photothermal conversion efficiency of water, CuS-MoS 2 -SH-PEG and MoS 2 at the same concentration and laser power density are compared in Fig. 5d . It is clear that CuS-MoS 2 -SH-PEG has a better photothermal conversion efficiency than MoS 2 .
To measure the photothermal stability of CuS-MoS 2 -SH-PEG, five on-off cycles of irradiation were carried out (Fig. 5e ). The temperature response of the CuS-MoS 2 -SH-PEG suspension remains largely constant. The UV-vis absorption spectra of CuS-MoS 2 -SH-PEG are also the same before and after five on-off cycles ( Fig. 5f ). These findings suggest that CuS-MoS 2 -SH-PEG has excellent photothermal stability. The photothermal conversion efficiency (Fig. S2 ) of CuS-MoS 2 -SH-PEG was calculated as 59.3%, superior to that reported for another modified MoS 2 system in a previous report [48] . 
In vitro cell viability
The cytocompatibility and therapeutic efficacy of the nanocomposites were evaluated in MCF-7 cells using MTT assays. The cell viabilities of cells treated with either PBS 19 / 31 or NIR and PBS alone were identical (> 90%), indicating that NIR alone has no effect on cell viability (Fig. S3 ). The results obtained with the other five treatments are shown in Fig. 6 . Cells exposed to CuS-MoS 2 -SH-PEG alone had high viabilities at 85% or more even with dosing at 10 μg/mL. The carrier thus has good biocompatibility. 
Cellular uptake
The passive targeting ability of the nanocomposites was investigated by CLSM.
MCF-7 cells were cultured with free DOX or CuS-MoS 2 -SH-PEG(DOX). The MCF-7 cells could take up both free DOX and CuS-MoS 2 -SH-PEG(DOX), as shown by the coincident presence of DAPI (blue) and DOX (red) fluorescence (Fig. 7) . This effect is minimal in the case of free DOX, but much more noticeable when the DOX is loaded on the nanocarrier. There is hence greater cellular uptake of rendering it more permeable [50, 51] . Overall, these results suggest that the CuS-MoS 2 -SH-PEG(DOX) formulation can efficiently deliver DOX into MCF-7 cells, which is beneficial for combined chemo-photothermal therapy. However, it should be noted that less DOX fluorescence was observed here compared to other MoS 2 -based systems conjugated with ligands for receptor-mediated uptake and active targeting [26, 48] . This confirms the benefits of using targeting ligands to enhance cellular uptake. displays pH-responsive and NIR induced drug release behavior, which is promising for tumor-specific delivery. In vitro studies found that the cytotoxicity of the CuS-MoS 2 -SH-PEG(DOX) formulation is greatest when NIR irradiation is applied, and the application of combined chemo-photothermal therapy led to greater cell death than either monotherapy alone (chemotherapy or photothermal therapy [PTT]). The cellular uptake of CuS-MoS 2 -SH-PEG(DOX) by cancer cells was much greater than that of free DOX, and was enhanced by NIR exposure. Overall, our study suggests that the CuS-MoS 2 -SH-PEG nanoparticles may be a promising platform for advanced anti-cancer therapeutics, and offers significantly enhanced PTT efficacy over previous reports of functionalized MoS 2 systems [48] . Our approach provides a strategy to enhance photothermal efficacy for a range of transition metal dichalcogenide drug delivery systems.
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